Breaking News - The Fly

Open Search

AXSM

Axsome Therapeutics

$

()

Axsome Therapeutics initiates ENGAGE Phase 3 trial of solriamfetol

AXSM

4/1/2024 - 07:17am

Axsome Therapeutics price target raised by $1 at Mizuho, here's why

AXSM

3/28/2024 - 06:39am

Axsome Therapeutics price target raised by $5 at RBC Capital, here's why

AXSM

3/26/2024 - 07:23am

Axsome Therapeutics price target raised by $10 at H.C. Wainwright, here's why

AXSM

3/26/2024 - 06:10am

Citi ups Axsome Therapeutics target, says selloff unwarranted

AXSM

3/26/2024 - 05:10am

Axsome Therapeutics announces results of CRESCENDO narcolepsy survy

AXSM

3/25/2024 - 07:05am

Axsome Therapeutics says AXS-12 achieves primary endpoint in SYMPHONY trial

AXSM

3/25/2024 - 06:34am

Axsome Therapeutics initiates PARADIGM Phase 3 trial of Solriamfetol

AXSM

3/19/2024 - 07:03am

Axsome Therapeutics initiated with bullish view at Baird, here's why

AXSM

3/18/2024 - 16:33pm

Axsome Therapeutics price target lowered by $4 at Mizuho, here's why

AXSM

2/27/2024 - 06:36am

Axsome Therapeutics price target lowered by $3 at RBC Capital, here's why

AXSM

2/21/2024 - 07:58am

Axsome Therapeutics price target lowered by $4 at UBS, here's why

AXSM

2/21/2024 - 07:16am

Axsome Therapeutics price target raised by $15 at Guggenheim, here's why

AXSM

2/21/2024 - 07:11am

Axsome Therapeutics reports Q4 EPS ($2.08), consensus ($1.17)

AXSM

2/20/2024 - 07:09am

Axsome Therapeutics price target raised by $22 at Mizuho, here's why

AXSM

2/15/2024 - 06:46am